Cassava Sciences Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while abrdn Physical Palladium Shares ETF trades at $24.83. The key difference: abrdn Physical Palladium Shares ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | PALL | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $4.64 | $37.18 |
52-Week Low | $0.87 | $19.96 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $24.87, down 0.96% over 24 hours. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, though oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a buying opportunity. The ETF provides exposure to physical palladium, which has declined 47% from January 2026 highs.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial demand recovery. Investment opportunity exists if palladium prices rebound from current depressed levels, supported by supply risks and potential catch-up trade. Key risks include continued commodity price volatility, Federal Reserve policy uncertainty, and weaker industrial demand affecting palladium's fundamental drivers.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →